Application of scalp cooling cap to reduce alopecia in breast cancer patients with neoadjuvant chemotherapy

doi:10.3877/cma.j.issn.1674-0807.2018.06.005

Abstract

Abstract:

Objective

To explore the application of scalp cooling cap in breast cancer patients with neoadjuvant chemotherapy.

Methods

We enrolled 100 breast cancer patients in Department of Breast Diseases, General Hospital of Lanzhou Military Command from January 2017 to December 2017 for a prospective study. All patients were equally divided into experimental group and control group using a random number table (50 cases in each group). The patients in two groups received neoadjuvant chemotherapy of FAC regimen (fluorouracil + doxorubicin + cyclophosphamide). During the chemotherapy period, the patients in experimental group wore a uniform scalp cooling cap and the patients in control group did not wear any scalp cooling cap. We compared hair loss rate between two groups after neoadjuvant chemotherapy. The clinical characteristics were compared between two groups by χ² test and the rank data pertaining to hair loss were compared using non-parametric test.

Results

The patients in experimental group reported no discomfort and delayed chemotherapy because of wearing the scalp cooling cap. Two weeks after chemotherapy, the hair loss rate was 48%(24/50) in experimental group and 84%(42/50) in the control group, indicating a significant difference between the two groups (χ²=14.439, P<0.001). There were 10 patients with grade 0 alopecia, 16 gradeⅠ, 5 grade Ⅱ, 8 grade Ⅲ and 11 grade Ⅳ in the experimental group, and 2, 6, 8, 12 and 22 in the control group, respectively. The difference between the two groups was statistically significant (Z=- 3.517, P<0.001).

Conclusion

The application of scalp cooling cap can significantly reduce alopecia in breast cancer patients during neoadjuvant chemotherapy. Scalp cooling cap is easy-to-use, effective and clinically feasible.

Key words: Breast neoplasms, Chemotherapy, Alopecia, Scalp cooling

Fan Chai, Yan Liang, Dawei Zhang, Yaqiong Huang, Ruli Qiao, Huiyun Yu, Li Chen. Application of scalp cooling cap to reduce alopecia in breast cancer patients with neoadjuvant chemotherapy[J]. Chinese Journal of Breast Disease(Electronic Edition), 2018, 12(06): 340-345.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2018.06.005

https://zhrxbzz.cma-cmc.com.cn/EN/Y2018/V12/I06/340

Figures/Tables 4

References 22

[1]	Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China in 2013: an analysis based on urbanization level [J]. Chin J Cancer Res, 2017, 29(1):1-10.
[2]	Hershman DL. Scalp cooling to prevent chemotherapy-induced alopecia. The time has come [J]. JAMA, 2017, 317(6):587-588.
[3]	Choi EK, Kim IR, Chang O, et al. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients [J]. Psychooncology, 2014, 23(10):1103-1110.
[4]	Cigler T, Isseroff D, Fiederlein B, et al. Efficacy of scalp cooling in preventing chemotherapy-induced alopecia in breast cancer patients receiving adjuvant docetaxel and cyclophosphamide chemotherapy [J]. Clin Breast Cancer, 2015, 15(5):332-334
[5]	van den Hurk CJ, van den Akker-van Marle ME, Breed WP, et al. Impact of scalp cooling on hemotherapy-induced alopecia, wig use and hair growth of patients with cancer [J]. Eur J Oncol Nurs, 2013, 17(5):536-540.
[6]	World Health Organization. WHO handbook for reporting results of cancer treatment [M]. Geneva: WHO, 1979：14-21.
[7]	Krug D. Prognostic factors for locoregional recurrence after neoadjuvant chemotherapy. Results of a combined analysis from NSABP B-18 and B-27 [J]. Strahlenther Onkol, 2013, 189(7):594-595.
[8]	Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27 [J]. J Clin Oncol, 2012, 30(32):3960-3966.
[9]	Rugo HS, Voigt J. Scalp hypothermia for preventing alopecia during chemotherapy. A systematic review and meta-analysis of randomized controlled trials [J]. Clin Breast Cancer, 2018, 18(1):19-28.
[10]	Nangia J, Wang T, Osborne C, et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer. The SCALP randomized clinical trial [J]. JAMA, 2017, 317(6):596-605.
[11]	Shin H, Jo SJ, Kim DH, et al. Efficacy of interventions for prevention of chemotherapy-induced alopecia: a systematic review and meta-analysis [J]. Int J Cancer, 2015, 136(5):E442-E454.
[12]	van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, et al. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients-results of the Dutch Scalp Cooling Registry [J]. Acta Oncol, 2012, 51(4):497-504.
[13]	Lemieux J, Desbiens C, Hogue JC. Breast cancer scalp metastasis as first metastatic site after scalp cooling: two cases of occurrence after 7- and 9-year follow-up [J]. Breast Cancer Res Treat, 2011, 128(2):563-566.
[14]	Rugo H, Melin SA, Voigt J. Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis [J]. Breast Cancer Res Treat, 2017, 163(2):199-205.
[15]	van den Hurk CJ, van de Poll-Franse LV, Breed WP, et al. Scalp cooling to prevent alopecia after chemotherapy can be considered safe in patients with breast cancer [J]. Breast, 2013, 22(5):1001-1004.
[16]	Komen MM, Smorenburg CH, van den Hurk CJ, et al. Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia [J]. Oncologist, 2013, 18(7):885-891.
[17]	Lemieux J, Provencher L, Perron L, et al. No effect of scalp cooling on survival among women with breast cancer [J]. Breast Cancer Res Treat, 2015, 149(1):263-268.
[18]	Belum VR, de Barros Silva G, Laloni MT, et al. Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia [J]. Breast Cancer Res Treat, 2016, 157(2):395-400.
[19]	van den Hurk CJ, Winstanley J, Young A, et al. Measurement of chemotherapy-induced alopecia-time to change [J]. Support Care Cancer, 2015, 23(5):1197-1199.
[20]	Rugo HS, Klein P, Merlin SA, et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer [J]. JAMA, 2017, 317(6):606-614
[21]	Rugo HS, Klein P, Melin SA, et al. Clinical performance of the DigniCap system, a scalp hypothermia system, in preventing chemotherapy-induced alopecia[EB/OL]. [2018-01-06]. URL
[22]	Rugo HS, Serrurier KM, Melisko M, et al. Use of the DigniCap™ system to prevent hair loss in women receiving chemotherapy (CTX) for stage I breast cancer (BC) [EB/OL]. [2018-01-06]. URL

指标		实验组(n＝50)	对照组(n＝50)	χ²值	P值
年龄		?	?	?	?
?	≤52岁	28	29	0.041	0.840
?	>52岁	22	21	0.041	0.840
月经状态		?	?	?	?
?	未绝经	32	34	0.178	0.673
?	已绝经	18	16	0.178	0.673
ER表达		?	?	?	?
?	阳性	40	42	0.271	0.603
?	阴性	10	8	0.271	0.603
PR表达		?	?	?	?
?	阳性	36	31	1.131	0.288
?	阴性	14	19	1.131	0.288
HER-2表达		?	?	?	?
?	阳性	11	8	0.585	0.444
?	阴性	39	42	0.585	0.444
Ki67表达		?	?	?	?
?	<14%	20	24	0.649	0.420
?	≥14%	30	26	0.649	0.420

指标		实验组(n＝50)	对照组(n＝50)	χ²值	P值
年龄		?	?	?	?
?	≤52岁	28	29	0.041	0.840
?	>52岁	22	21	0.041	0.840
月经状态		?	?	?	?
?	未绝经	32	34	0.178	0.673
?	已绝经	18	16	0.178	0.673
ER表达		?	?	?	?
?	阳性	40	42	0.271	0.603
?	阴性	10	8	0.271	0.603
PR表达		?	?	?	?
?	阳性	36	31	1.131	0.288
?	阴性	14	19	1.131	0.288
HER-2表达		?	?	?	?
?	阳性	11	8	0.585	0.444
?	阴性	39	42	0.585	0.444
Ki67表达		?	?	?	?
?	<14%	20	24	0.649	0.420
?	≥14%	30	26	0.649	0.420

组别	例数	0级	Ⅰ级	Ⅱ级	Ⅲ级	Ⅳ级
对照组	50	2(4)	6(12)	8(16)	12(24)	22(44)
实验组	50	10(20)	16(32)	5(10)	8(16)	11(22)
Z值	?	?	－3.517		?	?
P值	?	?	<0.001		?	?

组别	例数	0级	Ⅰ级	Ⅱ级	Ⅲ级	Ⅳ级
对照组	50	2(4)	6(12)	8(16)	12(24)	22(44)
实验组	50	10(20)	16(32)	5(10)	8(16)	11(22)
Z值	?	?	－3.517		?	?
P值	?	?	<0.001		?	?

Please choose a citation manager

Content to export